| |
著者: Maria E Cabanillas, Renata Ferrarotto, Adam S Garden, Salmaan Ahmed, Naifa L Busaidy, Ramona Dadu, Michelle D Williams, Heath Skinner, G Brandon Gunn, Horiana Grosu, Priyanka Iyer, Marie Claude Hofmann, Mark Zafereo
雑誌名: Thyroid. 2018 Jul;28(7):945-951. doi: 10.1089/thy.2018.0060. Epub 2018 Jun 29.
Abstract/Text
Anaplastic thyroid cancer (ATC) is a devastating disease with a dismal prognosis. Patients who have disease confined to the thyroid and who are able to undergo complete surgery and chemoradiation stand the best chance for survival. Unfortunately, nearly 50% of patients have distant metastases at diagnosis, and most present with locally advanced, unresectable tumors. Nevertheless, BRAF-mutated ATC patients represent a subset of cases who can benefit from a combination therapy with BRAF and MEK inhibitors. Here, a patient is presented with end-stage, locally advanced, unresectable ATC who was treated with this combination. Immunotherapy with pembrolizumab was added at the first sign of progression after which he achieved a partial response to therapy, enabling a complete surgical resection followed by postoperative chemoradiation to be undertaken. This novel neoadjuvant approach to BRAF-mutated ATC should be studied in further in clinical trials.
PMID 29742974 Thyroid. 2018 Jul;28(7):945-951. doi: 10.1089/thy.2018.0060. Epub 2018 Jun 29.
|
